1h
Hosted on MSNRoyalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 TransitionRoyalty Pharma PLC (RPRX) has disclosed a new risk, in the Regulation category. The planned internalization of Royalty Pharma LLC by RP Holdings, ...
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word (s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma records good start into fiscal year and confirms full year outlook 13.02.2025 / ...
In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), ...
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...
We recently compiled a list of the Top 10 Must-See AI News Updates for Investors. In this article, we are going to take a ...
Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies ...
Outperformance during the fourth quarter primarily resulted from stock selection and an overweight in industrials. Read more ...
CNW/ - Canada Pension Plan Investment Board (CPP Investments) ended its third quarter on December 31, 2024, with net assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results